Cargando…

Prior Authorization to Manage Drug Utilization and Costs

Detalles Bibliográficos
Autor principal:	Curtiss, Frederic R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2003
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437155/ https://www.ncbi.nlm.nih.gov/pubmed/14613376 http://dx.doi.org/10.18553/jmcp.2003.9.1.95a

Ejemplares similares

Prior Authorization and Clopidogrel Use - The Truth Lies in the Details
por: Jackson, Mark A., et al.
Publicado: (2009)

Burden of Prescription Drug Costs in the United States
por: Curtiss, Frederic R.
Publicado: (2003)

What Are Prior Authorization and the Formulary Exception Process?
por: Curtiss, Frederic R.
Publicado: (2005)

Contractual Arrangements Between HMOs and Medical Groups to Manage Drug Costs
por: Curtiss, Frederic R.
Publicado: (2003)

HIPAA Effects on Health Research and PBM Functions in Drug Utilization Review
por: Curtiss, Frederic R.
Publicado: (2003)

Pressure on Pharmacy Benefit Managers for Disclosure and Demonstration of Value - Rebates and Drug Benegit Cost Savings
por: Curtiss, Frederic R.
Publicado: (2003)

Finding the Truth About Health Care Cost Drivers - Price Versus Utilization Factors
por: Curtiss, Frederic R.
Publicado: (2003)

Effects of Physician Report Cards, Knowledge of Drug Prices, and Financial Incentives in Prescription Drug Costs
por: Curtiss, Frederic R.
Publicado: (2003)

Utilization Management Opportunities for Palivizumab for Prophylaxis of Respiratory Syncytial Virus Complications in Infants
por: Curtiss, Frederic R., et al.
Publicado: (2010)

Clinical, Service, and Cost Outcomes of Drug Coverage Edits and Quanitity Limits
por: Curtiss, Frederic R.
Publicado: (2003)

David and Goliath - Employer Takes on Health Care Cost Management
por: Curtiss, Frederic R.
Publicado: (2004)

Omalizumab and Other New Drug Therapies Occupy a Small Space in Asthma Disease Management
por: Curtiss, Frederic R.
Publicado: (2009)

More Evolution of the Evidence in Asthma Disease Management-SMART Versus GOAL Clinical Trials Debate the Cost-Benefit of LABA While the Value of Leukotriene Modifiers, Particularly Montelukast, Is Uncertain
por: Curtiss, Frederic R.
Publicado: (2006)

Value for Money in Disease Management of Acute Coronary Syndrome - The Price of Aspirin to Reduce the Costs of ACS
por: Curtiss, Frederic R.
Publicado: (2005)

Selectivity and Specificity Are the Keys to Cost-Effective Use of Omalizumab for Allergic Asthma
por: Curtiss, Frederic R.
Publicado: (2005)

The association between cost sharing, prior authorization, and specialty drug utilization: A systematic review
por: Ismail, Wesam W, et al.
Publicado: (2023)

How Do Seniors Respond to 100% Cost-Sharing for Prescription Drugs? Quality of the Evidence Underlying Opinions About the Medicare Part D Coverage Gap
por: Fairman, Kathleen A., et al.
Publicado: (2011)

False-Positive Versus True-Positive Drug-Drug Interactions With Warfarin
por: Curtiss, Frederic R.
Publicado: (2006)

The Relative Value of Disease Management Programs Versus Drug Manufacturer Rebates
por: Curtiss, Frederic R.
Publicado: (2003)

Heartburn in Consumer-Directed Health Care and the Cost Outcomes of Therapeutic Maximum Allowable Cost
por: Curtiss, Frederic R.
Publicado: (2006)

Preventing Medication Errors and Adverse Drug Events
por: Curtiss, Frederic R.
Publicado: (2003)

COX-2 Inhibitors: Little or No GI Protection, Increased Risk of Cardiovascular Events, High Cost, and Other Class-less Effects
por: Curtiss, Frederic R.
Publicado: (2005)

Medicare PPOs and Managed Care
por: Curtiss, Frederic R.
Publicado: (2003)

VBID, the PPACA, and FREEE Medications: Did Politics Trump the Evidence About Cost Sharing?
por: Fairman, Kathleen A., et al.
Publicado: (2012)

Antihypertensive Drug Effects on Renal Function and Myocardial Infarction and Implications of the ALLHAT Study Results
por: Curtiss, Frederic R.
Publicado: (2003)

Pharmacy Benefit Spending Poised to Increase for Antithrombotic Drug Therapy--Prasugrel Versus Clopidogrel
por: Curtiss, Frederic R.
Publicado: (2009)

Asthma Disease Management-Evidence-Based Medicine Must Be Dynamic
por: Curtiss, Frederic R.
Publicado: (2006)

Pharmacoeconomics - Determiniation of the Cost-Effectiveness of Helicobacter Pylori Eradication
por: Curtiss, Frederic R.
Publicado: (2003)

Protecting Patients from Adverse Drug Events: Propoxyphene, PIMs, and Drugs to Avoid in Older Adults
por: Curtiss, Frederic R., et al.
Publicado: (2011)

Contradictory Actions on Off-Label Use of Prescription Drugs? The FDA and CMS Versus the U.S. Justice Department
por: Curtiss, Frederic R.
Publicado: (2009)

Is Buprenorphine-Naloxone Ready for Prime Time in the Treatment of Opioid Addiction in Managed Care?
por: Curtiss, Frederic R.
Publicado: (2008)

Which Triptan? - Opportunity for Same or Better Outcomes at Lower Cost
por: Curtiss, Frederic R.
Publicado: (2004)

Clinical, Service, and Cost Outcomes of Computerized Prescription Order Entry
por: Curtiss, Frederic R.
Publicado: (2005)

Chasing Quality - Clinical Practice Guidelines and HEDIS Measures of Asthma and Depression Therapy Management
por: Curtiss, Frederic R.
Publicado: (2006)

Hypertension, Prescription Drug Copayments, and Drug Therapy Adherence
por: Curtiss, Frederic R.
Publicado: (2003)

Reducing the Risk of Fractures - The Options Narrow for Cost-Effective Therapeutic Alternatives
por: Curtiss, Frederic R.
Publicado: (2004)

Diabetes Drug Therapy -- First Do No Harm
por: Curtiss, Frederic R., et al.
Publicado: (2008)

Does Member Cost Sharing Pose a Threat to Desirable Patient Outcomes?
por: Curtiss, Frederic R.
Publicado: (2004)

Looking for the Outcomes We Love in All the Wrong Places: The Questionable Value of Biomarkers and Investments in Chronic Care Disease Management Interventions
por: Curtiss, Frederic R.
Publicado: (2008)

PandT Committees - Black Boxes Versus AMCP Format, and What Is the True Cost and Value of Pimecrolimus
por: Curtiss, Frederic R.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_umdka4rqkktermo01dpi7ll7g5